NOVARTIS

NOVARTIS logo
🇨🇭Switzerland
Ownership
Public, Private
Established
1996-01-01
Employees
76K
Market Cap
$242.6B
Website
https://www.novartis.com/our-science/novartis-institutes-biomedical-research

Efficacy and Safety of AFQ056 in Reducing L-dopa Induced Dyskinesias in Parkinson's Disease Patients

First Posted Date
2009-04-24
Last Posted Date
2016-04-19
Lead Sponsor
Novartis
Target Recruit Count
28
Registration Number
NCT00888004
Locations
🇩🇪

Novartis Investigative Site, Tubingen, Germany

Efficacy of BGG492 in Individuals With Refractory Partial Seizures Undergoing Inpatient Evaluation for Epilepsy Surgery

Phase 2
Completed
Conditions
Interventions
First Posted Date
2009-04-24
Last Posted Date
2017-03-21
Lead Sponsor
Novartis
Target Recruit Count
37
Registration Number
NCT00887861
Locations
🇩🇪

Novartis Investigator Site, Munich, Germany

Safety and Efficacy of Aliskiren + Hydrochlorothiazide (± Amlodipine 5 mg) in Patients With Moderate Hypertension

First Posted Date
2009-03-23
Last Posted Date
2011-05-06
Lead Sponsor
Novartis
Target Recruit Count
186
Registration Number
NCT00867490
Locations
🇩🇪

Investigative Site, Chemnitz, Germany

Efficacy and Safety of Aliskiren 300 mg Compared to Telmisartan 80 mg After 1 Week of Treatment Withdrawal

First Posted Date
2009-03-19
Last Posted Date
2011-07-22
Lead Sponsor
Novartis
Target Recruit Count
822
Registration Number
NCT00865020
Locations
🇻🇪

Investigative Site, Caracas, Venezuela

🇭🇺

Invesitagtive Site, Budapest, Hungary

A Study to Investigate the Bronchodilatory Effect of NVA237 in Patients With Chronic Obstructive Pulmonary Disease (COPD)

First Posted Date
2009-03-05
Last Posted Date
2016-09-14
Lead Sponsor
Novartis
Target Recruit Count
33
Registration Number
NCT00856193
Locations
🇩🇪

Harrison Clinical Research Deutschland GmbH, Albrechtstrasse 14, Munich, Germany

🇺🇸

Spartanburg Medical Research, Spartanburg, South Carolina, United States

Efficacy and Safety of Aliskiren Administered in Combination With Amlodipine Versus Amlodipine Alone in African American Patients With Stage 2 Hypertension

Phase 4
Completed
Conditions
Interventions
First Posted Date
2009-03-02
Last Posted Date
2012-04-30
Lead Sponsor
Novartis
Target Recruit Count
443
Registration Number
NCT00853957
Locations
🇺🇸

Investigative Site, Milwaukeee, Wisconsin, United States

A Dose Ranging Study Comparing Different Combinations of Adjuvanted and Non-adjuvanted Influenza Vaccines in Healthy Children 6 to <36 Months of Age

First Posted Date
2009-02-20
Last Posted Date
2014-01-24
Lead Sponsor
Novartis
Target Recruit Count
410
Registration Number
NCT00848887
Locations
🇧🇪

UCL St. Luc - Pharmacy, Brussel, Belgium

Efficacy and Safety of the Combination of Aliskiren (300 mg) and Amlodipine (10 mg) Compared to Amlodipine (10 mg) Monotherapy in Patients With Moderate to Severe Hypertension

First Posted Date
2009-02-11
Last Posted Date
2011-07-12
Lead Sponsor
Novartis
Target Recruit Count
485
Registration Number
NCT00841672
Locations
🇪🇸

Investigative Site, Madrid, Spain

Safety, Tolerability and Immunogenicity of Two Doses of Adjuvanted Monovalent Influenza Vaccine Administered to Healthy Adult and Elderly Subjects

First Posted Date
2009-02-11
Last Posted Date
2021-04-23
Lead Sponsor
Novartis
Target Recruit Count
3647
Registration Number
NCT00841763
Locations
🇩🇪

12 Sites, München, Germany

🇫🇮

Tampere Vaccine Research Clinic (15 sites), Tampere, Finland

A Study to Evaluate the Safety/Tolerability and Pharmacokinetics of Aliskiren in Hypertensive Pediatric and Adolescent Patients 6-17 Years of Age

Phase 1
Completed
Conditions
Interventions
First Posted Date
2009-02-03
Last Posted Date
2011-05-09
Lead Sponsor
Novartis
Target Recruit Count
39
Registration Number
NCT00834041
Locations
🇵🇱

Investigative Site, Warsaw, Poland

© Copyright 2024. All Rights Reserved by MedPath